Do Not Do Recommendation

 

Pirfenidone is recommended as an option for treating idiopathic pulmonary fibrosis only if: - the person has a forced vital capacity (FVC) between 50% and 80% predicted and - the manufacturer provides pirfenidone with the discount agreed in the patient access scheme. Treatment with pirfenidone that is recommended as above should be discontinued if there is evidence of disease progression (a decline in per cent predicted FVC of 10% or more within any 12 month period).

Do Not Do Recommendation Details

Recommendation:

Pirfenidone is recommended as an option for treating idiopathic pulmonary fibrosis only if: - the person has a forced vital capacity (FVC) between 50% and 80% predicted and - the manufacturer provides pirfenidone with the discount agreed in the patient access scheme. Treatment with pirfenidone that is recommended as above should be discontinued if there is evidence of disease progression (a decline in per cent predicted FVC of 10% or more within any 12 month period).

Interventions:
Pirfenidone

Source guidance details

Guidance:
Pirfenidone for treating idiopathic pulmonary fibrosis (TA282)
Published date:
April 2013
Paragraph number:
1.2
Page number:
3

View all NICE do not do from this Guidance

There are no other recommendations for this guidance.